228
Views
65
CrossRef citations to date
0
Altmetric
Original Research

Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment)

, , , , &
Pages 327-338 | Published online: 14 Jan 2016

Figures & data

Figure 1 Study flow.

Figure 1 Study flow.

Table 1 Baseline demographics and characteristics (safety population)

Table 2 The ratios of plasma trough concentrations during day 2 – week 10 to the last day of treatment (week 12) (pharmacokinetic analysis population)

Figure 2 Plasma concentrations of cariprazine (A), desmethyl-cariprazine (B), didesmethyl-cariprazine (C) and total active moieties (sum of cariprazine, desmethyl-cariprazine and didesmethyl-cariprazine) (D) for each dose group during the treatment and follow-up periods.

Notes: Data are mean + standard deviation. The lower limit of quantification of analytes was 0.02 ng/mL. The mean was not plotted when at least half of the results were below the lower limit of detection except at time =0.
Figure 2 Plasma concentrations of cariprazine (A), desmethyl-cariprazine (B), didesmethyl-cariprazine (C) and total active moieties (sum of cariprazine, desmethyl-cariprazine and didesmethyl-cariprazine) (D) for each dose group during the treatment and follow-up periods.

Table 3 Pharmacokinetic parameters measured on the first and last days of the 12-week treatment period (pharmacokinetic analysis population)

Table 4 Summary of adverse events

Table 5 Summary of efficacy assessments (efficacy analysis population)